Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

被引：6
|
作者：
Fiorelli, Alfonso [1 ]
Vitiello, Fabiana [2 ]
Morgillo, Floriana [3 ]
Santagata, Mario [4 ]
Spuntarelli, Chiara [4 ]
Di Domenico, Marina [5 ]
Santini, Mario [1 ]
Bianco, Andrea [6 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Thorac Surg Unity, Dept Translat Med Sci, Naples, Italy
[2] Hosp Vincenzo Monaldi, Dept Pneumol & Oncol, Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Oncol Unit, Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Maxillo & Orofacial Unit, Naples, Italy
[5] Univ Campania Luigi Vanvitelli, Gen Pathol Unit, Naples, Italy
[6] Univ Campania Luigi Vanvitelli, Pneumol Unity, Dept Translat Med Sci, Naples, Italy
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
D O I：
10.21037/tcr.2019.06.28
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S618 / S620
页数：3
相关论文
共 50 条
  • [31] Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study
    Lin, D.
    Yang, X.
    Jiang, L.
    Wang, W.
    Hou, Y.
    Li, Y.
    Jin, Y.
    Fan, X.
    Sun, W.
    Yun, J.
    Li, P.
    Kuang, D.
    Zhang, L.
    Ni, J.
    Mao, A.
    Tang, W.
    Liu, Z.
    Wang, J.
    Xiao, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S410 - S410
  • [32] Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
    Jung, Hyun Ae
    Park, Sehhoon
    Choi, Yoon-La
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Sun, Jong-Mu
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2321 - 2328
  • [33] Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
    John, Nikolaus
    Schlintl, Verena
    Sassmann, Teresa
    Lindenmann, Joerg
    Fediuk, Melanie
    Wurm, Robert
    Douschan, Philipp
    Zacharias, Martin
    Kalson, Lipika
    Posch, Florian
    Absenger, Gudrun
    Brcic, Luka
    Jost, Philipp J.
    Terbuch, Angelika
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [34] BUDGET IMPACT MODEL OF PEMBROLIZUMAB IN PREVIOUSLY TREATED ADVANCED PD-L1 NSCLC POSITIVE IN COLOMBIA
    Huang, M.
    Arunachalam, A.
    Chandwani, S.
    Monsanto, H.
    Beltran, C.
    Rojas, M.
    Hinestrosa, F.
    Restrepo, M.
    Ordosgoitia, A.
    Martinez, I
    VALUE IN HEALTH, 2017, 20 (05) : A97 - A97
  • [35] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
    Chen, Ya
    Wang, Yanan
    Yang, Zhengyu
    Hu, Minjuan
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    THORACIC CANCER, 2015, 6 (04) : 534 - 538
  • [37] Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
    Sanchez-Gastaldo, Amparo
    Munoz-Fuentes, Miguel A.
    Molina-Pinelo, Sonia
    Alonso-Garcia, Miriam
    Boyero, Laura
    Bernabe-Caro, Reyes
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2509 - +
  • [38] Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues
    Yu, S.
    Shi, M.
    Feng, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
    Chen, Justin A.
    Riess, Jonathan W.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (07)
  • [40] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
    Justin A. Chen
    Jonathan W. Riess
    Current Treatment Options in Oncology, 2020, 21
12345